Cytori Therapeutics Announced Inducement Grant for New Employee

Cytori Therapeutics, Inc. (NASDAQ:CYTX), a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, announced today that the Compensation Committee of the Company's Board of Directors granted to Mark Marino, M.D., Senior Vice President of Clinical Affairs, a non-qualified stock option to purchase an aggregate of 33,333 shares of the Company's common stock (the “Option Shares”) with a per share exercise price of $2.18, the closing price of Cytori’s common stock on August 4th, 2016, the date of the grant. The stock option has a ten-year term and vests over a period of four years, with one quarter of the Option Shares scheduled to vest on May 23, 2017 (the first anniversary of Dr. Marino’s employment commencement date with Cytori), and the remainder of the Option Shares vesting over the ensuing three years in thirty-six (36) equal, consecutive, monthly installments, in each case subject to Dr. Marino’s continued employment with Cytori as of the respective vesting dates. The stock option is subject to the terms and conditions of Cytori's 2015 New Employee Incentive Plan and the stock option agreement pursuant to which the stock option is granted.

The stock option was granted as an inducement material to Dr. Marino’s entering into employment with Cytori in accordance with NASDAQ Listing Rule 5635(c)(4).

View source version on businesswire.com: http://www.businesswire.com/news/home/20160805005739/en/

Cytori TherapeuticsTiago [e-mail]